A phase II dose expansion of TH-302 in combination with doxorubicin in soft-tissue sarcoma.
L. D. Cranmer
Consultant or Advisory Role - Threshold Pharmaceuticals (U)
Research Funding - Threshold Pharmaceuticals
K. N. Ganjoo
No relevant relationships to disclose
D. Adkins
No relevant relationships to disclose
D. R. Reed
No relevant relationships to disclose
S. H. Okuno
No relevant relationships to disclose
J. E. Butrynski
No relevant relationships to disclose
D. A. Rushing
No relevant relationships to disclose
G. A. Lorente
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
S. Kroll
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
S. P. Chawla
No relevant relationships to disclose